LIONVILLE, Pa. (Oct. 20)—West Pharmaceutical Services Inc. has reported net income of $4.6 million for the third quarter 2000, compared with $8.6 million for the same period of 1999. Strong European and Asian Pacific sales growth could not overcome weaker-than-expected North American demand in the device product development sector, West said, and a strong U.S. dollar negatively affected reported results of international subsidiaries. West also announced its directors have authorized UBS Warburg L.L.C. to review all of West´s strategic alternatives and identify possible means to bolster shareholder value, including dispositions of assets or business combinations. No further comment will be made on the matter, pending the review, West said.
West, as profits slip, seeks "strategic alternatives"
Rubber News wants to hear from its readers. If you want to express your opinion on a story or issue, email your letter to Editor Bruce Meyer at [email protected].